A bitter dispute over when women should begin routine mammography has erupted in the United States, exposing a widening gap between clinical guidance and frontline medical experience. The American College of Physicians now recommends that average-risk women start biennial screening at 50, with those aged 40 to 49 advised to make individual decisions with their doctors rather than undergo automatic mammograms. Breast surgeons were immediate and blunt in their condemnation. Amani Jambhekar, a surgical oncologist in Delaware, urged patients to ignore the new guidelines, arguing that they ignore what doctors see daily: cancers detected earlier precisely because of screening in the forties. The controversy reflects a deeper global tension between population-level cost-effectiveness and the lived reality of cancer care.

Across the Atlantic, ovarian cancer presents an even more insidious challenge. Viewed from Delhi, the disease is a particular cruelty: it stirs quietly with vague bloating or back pain, often diagnosed only after it has spread. This year’s World Ovarian Cancer Day theme, ‘No Woman Left Behind’, underscores how far too many women are being abandoned by late diagnosis and underfunded research. In Iran, ovarian cancer ranks as the fourth most common malignancy among women, behind breast, colorectal, and skin cancers. Specialists in Tehran note that most cases are diagnosed at advanced stages because early symptoms are subtle or absent, and no definitive prevention exists beyond long-term oral contraceptive use.

The structural failures of public health systems compound these biological realities. In Mexico, nearly three thousand breast cancer patients have documented catastrophic delays in diagnosis, drug shortages, and treatment abandonment through a national survey. Susy de León, one of the women who shared her story, described losing her home and car to the disease. Analysts in Mexico City point out that six out of ten women detected their own tumours, indicating that the system is failing even in the most basic surveillance.

Treatment itself carries a hidden burden. For the estimated 70 to 80 percent of breast cancers that are hormone-receptor-positive, endocrine therapies induce severe menopausal symptoms—hot flushes, insomnia, fatigue—that can become so debilitating that patients abandon essential treatment. Specialists increasingly argue that managing these side effects is no longer optional but a core component of public health strategy.

Screening adherence also remains stubbornly low in some populations. In Sweden, where colorectal cancer affects over six thousand people annually, a home-screening programme for men and women aged 60 to 74 reaches only four in ten men in Norrbotten. The most common reasons are forgetfulness and reluctance. “Uteblivna test innebär en ökad risk för att cancer upptäcks sent,” warns surgeon Olof Sjöström. The pattern is familiar: well-designed screening tools exist, but behavioural and systemic barriers persist.

The common thread across these disparate stories is the tension between clinical evidence and real-world implementation. Preventive health tests—HPV, diabetes, breast, and cervical screenings—are widely recommended for women after their twenties, yet uptake varies drastically. The way forward demands not only better guidelines but also more robust public health infrastructure, honest conversations about side effects, and a recognition that early detection cannot be achieved without addressing the human factors that cause patients to delay, decline, or abandon care.